Literature DB >> 26908435

Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor.

Øivind Kvammen1, Tor Å Myklebust2, Arne Solberg3, Bjørn Møller2, Olbjørn H Klepp4, Sophie D Fosså5, Torgrim Tandstad3.   

Abstract

BACKGROUND: Long-term relative survival (RS) data for testicular germ cell tumor (TGCT) patients are scarce. We aimed to analyze long-term RS among TGCT patients diagnosed in Norway, between 1953 and 2012.
METHODS: Data sources were the Cancer Registry of Norway and the Norwegian Cause of Death Registry. TGCT patients diagnosed during 1953 to 2012 were classified by time of diagnosis, histology, age, and disease extent at diagnosis. Estimates for RS were obtained, and a test comparing overall RS was performed. Corresponding data were obtained for men diagnosed with localized malignant melanoma before age 50.
RESULTS: A total of 8,736 TGCT patients were included. RS generally continued to decline with increasing follow-up time, particularly beyond 15 to 30 years, unlike in localized malignant melanoma. Although RS was generally higher for seminomas, the continuing decline was more pronounced than for nonseminomas, even when diagnosed with localized disease. TGCT patients diagnosed before 1980 or after age 40 had lower RS.
CONCLUSIONS: Although TGCT RS has improved in recent decades, it continues to decline even beyond 30 years of follow-up, regardless of disease extent at diagnosis. The main cause is probably treatment-induced late effects, particularly affecting seminoma patients. The continued use of adjuvant radiotherapy in seminomas until year 2000 is suspected as a culprit. IMPACT: Long-term TGCT survivors should be closely monitored for the development of late comorbidity. The challenge is to reduce negative consequences of previous and current TGCT treatment on RS while maintaining the excellent cure rates. Further research on causes of long-term morbidity and mortality among TGCT survivors is warranted. Cancer Epidemiol Biomarkers Prev; 25(5); 773-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 26908435     DOI: 10.1158/1055-9965.EPI-15-1153

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  11 in total

1.  Cancer survival in Qidong between 1972 and 2011: A population-based analysis.

Authors:  Jian-Guo Chen; Jian Zhu; Yong-Hui Zhang; Yi-Xin Zhang; Deng-Fu Yao; Yong-Sheng Chen; Jian-Hua Lu; Lu-Lu Ding; Hai-Zhen Chen; Chao-Yong Zhu; Li-Ping Yang; Yuan-Rong Zhu; Fu-Lin Qiang
Journal:  Mol Clin Oncol       Date:  2017-05-03

Review 2.  Testicular cancer.

Authors:  Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga
Journal:  Nat Rev Dis Primers       Date:  2018-10-05       Impact factor: 52.329

3.  The primitive extratesticular seminoma: diagnosis of a rare pathology.

Authors:  Luca Saba
Journal:  Acta Biomed       Date:  2017-04-28

4.  Second cancers and causes of death in patients with testicular cancer in Sweden.

Authors:  Luyao Zhang; Otto Hemminki; Tianhui Chen; Hongyao Yu; Guoqiao Zheng; Subhayan Chattopadhyay; Asta Försti; Kristina Sundquist; Jan Sundquist; Kari Hemminki
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

5.  Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease.

Authors:  Joost M Blok; J Martijn Kerst; Erik Vegt; Oscar R Brouwer; Richard P Meijer; J L H Ruud Bosch; Axel Bex; Henk G van der Poel; Simon Horenblas
Journal:  BJU Int       Date:  2019-03-28       Impact factor: 5.588

6.  Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study.

Authors:  Øivind Kvammen; Tor Åge Myklebust; Arne Solberg; Bjørn Møller; Olbjørn Harald Klepp; Sophie Dorothea Fosså; Torgrim Tandstad
Journal:  PLoS One       Date:  2019-12-18       Impact factor: 3.240

7.  Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.

Authors:  A Fichtner; H Bohnenberger; S Kueffer; D Nettersheim; F Bremmer; O Elakad; A Richter; C Lenz; C Oing; P Ströbel
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 4.226

8.  Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.

Authors:  J L H Ruud Bosch; Joost M Blok; Henk G van der Poel; J Martijn Kerst; Axel Bex; Oscar R Brouwer; Simon Horenblas; Richard P Meijer
Journal:  World J Urol       Date:  2020-09-21       Impact factor: 4.226

9.  Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome.

Authors:  Cecilie Bucher-Johannessen; Christian M Page; Trine B Haugen; Marcin W Wojewodzic; Sophie D Fosså; Tom Grotmol; Hege S Haugnes; Trine B Rounge
Journal:  Clin Epigenetics       Date:  2019-12-03       Impact factor: 6.551

10.  Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study.

Authors:  Mette Pernille Myklebust; Anna Thor; Benedikte Rosenlund; Peder Gjengstø; Ása Karlsdottir; Marianne Brydøy; Bogdan S Bercea; Christian Olsen; Ida Johnson; Mathilde I Berg; Carl W Langberg; Kristine E Andreassen; Anders Kjellman; Hege S Haugnes; Olav Dahl
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.